Key regions: France, India, United Kingdom, South Korea, Japan
Central America is a region that has been experiencing significant growth in the pharmaceutical industry in recent years. The Multiple Sclerosis Drugs market in Central America is no exception to this trend.
Customer preferences: Patients suffering from Multiple Sclerosis in Central America are increasingly seeking treatments that can help them manage their symptoms and improve their quality of life. They are also becoming more aware of the range of treatment options available to them and are seeking the latest and most effective drugs.
Trends in the market: There has been a growing demand for disease-modifying therapies (DMTs) in Central America. These drugs can help slow down the progression of Multiple Sclerosis and reduce the frequency and severity of relapses. The market is also witnessing a shift towards oral DMTs, which are more convenient for patients compared to injectable DMTs. Another trend is the increasing use of biosimilars, which are drugs that are similar to existing biologic drugs but are less expensive.
Local special circumstances: Central America is a region with a high prevalence of Multiple Sclerosis. This has led to an increased focus on research and development of drugs for the treatment of the disease. The region also has a relatively young population, which means that there is a high demand for drugs that can help patients manage their symptoms and maintain their quality of life.
Underlying macroeconomic factors: The pharmaceutical industry in Central America is growing rapidly, driven by factors such as an increasing population, rising incomes, and a growing middle class. The region is also becoming more attractive to foreign investors, who are looking to tap into the growing market. Additionally, the region is home to a number of pharmaceutical companies that are investing heavily in research and development, which is driving innovation in the industry.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
